A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

BACKGROUND: The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically rele...

Descripción completa

Detalles Bibliográficos
Autores principales: Malyguine, Anatoli, Strobl, Susan L, Shafer-Weaver, Kimberly A, Ulderich, Tracy, Troke, Angela, Baseler, Michael, Kwak, Larry W, Neelapu, Sattva S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC415560/
https://www.ncbi.nlm.nih.gov/pubmed/15050026
http://dx.doi.org/10.1186/1479-5876-2-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC415560/
https://www.ncbi.nlm.nih.gov/pubmed/15050026
http://dx.doi.org/10.1186/1479-5876-2-9

Ejemplares similares